PREMARIN Package Insert Revision

This document is a final notice from the FDA concerning a revision to the PREMARIN package insert, specifically related to NDA #004782. While the exact nature of the revision is not detailed in the provided metadata, package insert updates typically involve changes to prescribing information, warnings, indications, or contraindications.

For drug manufacturers and pharmaceutical companies, this notice signifies an update to the approved labeling for PREMARIN. Compliance officers should ensure their internal documentation and product information reflect the revised package insert. While this is a final notice and not a proposed rule, it is crucial to obtain and review the updated insert to confirm any changes in recommended usage, safety information, or reporting requirements.